Observational studyFrontiers in immunology2021
Adalimumab Therapy Restores the Gut Microbiota in Patients With Ankylosing Spondylitis.
Observational study in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Ankylosing spondylitis and the gut microbiome: future research hotspots and trends.Frontiers in immunology · 2026Pooled it
- Age- and region-specific gut microbiota dysbiosis in axial spondyloarthritis: a systematic review and meta-analysis.Frontiers in immunology · 2026Pooled it
- Gut microbiota dysbiosis in ankylosing spondylitis: a systematic review and meta-analysis.Frontiers in cellular and infection microbiology · 2024Pooled it
- Gut dysbiosis in rheumatic diseases: A systematic review and meta-analysis of 92 observational studies.EBioMedicine · 2022Pooled it
- Recent antibiotic exposure and response to treatment of juvenile idiopathic arthritis: a retrospective cohort study.Arthritis research & therapy · 2026Article
- Metagenomic analysis of intestinal microbiota characteristic differences between patients with ankylosing spondylitis and healthy individuals.BMC microbiology · 2026Article
- Global research status and trends in the treatment of ankylosing spondylitis from 2005 to 2024: a bibliometric analysis.Clinical rheumatology · 2026Review
- Gut microbiota and uveitis: exploring novel mechanisms of inflammatory ocular diseases via the gut-eye axis.Frontiers in microbiology · 2026Review
- Role of Gut Microbiota and Metabolomics in Predicting Response to Vedolizumab in Inflammatory Bowel Disease: A Systematic Review.Pharmaceutics · 2025Review
- From Dysbiosis to Disease: The Microbiome's Influence on Uveitis Pathogenesis.Microorganisms · 2025Review
- Gut microbiota and ankylosing spondylitis: current insights and future challenges.Microbial cell (Graz, Austria) · 2025Review
- Precision medicine in axial spondyloarthritis: current opportunities and future perspectives.Therapeutic advances in musculoskeletal disease · 2024Review
- Review
- Spondyloarthritis with inflammatory bowel disease: the latest on biologic and targeted therapies.Nature reviews. Rheumatology · 2023Review
- The causal role of intestinal microbiome in development of pre-eclampsia.Functional & integrative genomics · 2023Article
- Identification of gut dysbiosis in axial spondyloarthritis patients and improvement of experimental ankylosing spondyloarthritis by microbiome-derived butyrate with immune-modulating function.Frontiers in immunology · 2023Article
- Molecular Characterisation of Blood Microbiome in Patients with Ankylosing Spondylitis and Healthy Controls.Medical journal of the Islamic Republic of Iran · 2023Article
- Association of gut microbiome and metabolites with onset and treatment response of patients with pemphigus vulgaris.Frontiers in immunology · 2023Article
- Case report: Fecal microbiota transplantation in refractory ankylosing spondylitis.Frontiers in immunology · 2023Article
- The Yin-Yang Pharmacomicrobiomics on Treatment Response in Inflammatory Arthritides: A Narrative Review.Genes · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growing evidence suggests that the gut microbiota is involved in the initiation and progression of ankylosing spondylitis (AS). In this study, we aimed to explore the gut microbiome alterations during adalimumab therapy and verify microbiome biomarkers predicting treatment response. By evaluating the gut microbial features of 30 AS patients before and after adalimumab therapy for 6 months and 24 healthy controls, we confirmed that the microbiome was restored remarkably after 6 months of adalimumab therapy in AS patients. We then compared the baseline gut microbiome of 22 adalimumab responders with 8 non-responders, a higher abundance of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.